Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Rubicon Genomics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013177
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) analysis, Aneuploidy, circulating tumor deoxyribose nucleic acid (ctDNA) analysis, and gene expression analysis. It employs high sensitivity ligation-based amplification, and quasi-random primed linear amplification technologies in its sequencing kits. Rubicon Genomics’ sequencing kits find applications in Formalin-fixed, paraffin-embedded (FFPE) DNA sequencing, DNA sequencing, ribose nucleic acid (RNA) sequencing, pre-implantation genetic screening and diagnosis (PGS, PGD), and chromatin immunoprecipitation sequencing (ChIP-seq). Rubicon Genomics is headquartered in Ann Arbor, Michigan, the US.

Rubicon Genomics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rubicon Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Rubicon Genomics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Rubicon Genomics Raises USD2 Million in Venture Financing 11
Partnerships 12
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 12
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 13
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 14
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 15
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 16
PerkinElmer Enters Into Distribution Agreement With Rubicon Genomics 17
Licensing Agreements 18
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 18
Acquisition 19
Takara Bio Acquires Rubicon Genomics for USD75 Million 19
Rubicon Genomics Inc – Key Competitors 20
Rubicon Genomics Inc – Key Employees 21
Rubicon Genomics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Other Significant Developments 23
Jan 11, 2016: Rubicon Genomics Adds New Distributors as Product Sales Continued to Accelerate in 2015 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rubicon Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rubicon Genomics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Rubicon Genomics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Rubicon Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rubicon Genomics Raises USD2 Million in Venture Financing 11
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 12
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 13
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 14
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 15
New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 16
PerkinElmer Enters Into Distribution Agreement With Rubicon Genomics 17
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 18
Takara Bio Acquires Rubicon Genomics for USD75 Million 19
Rubicon Genomics Inc, Key Competitors 20
Rubicon Genomics Inc, Key Employees 21

★海外企業調査レポート[Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dentsu Inc (4324):企業の財務・戦略的SWOT分析
    Dentsu Inc (4324) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Aeon Co., Ltd.:企業の戦略・SWOT・財務分析
    Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Puretech Health plc (PRTC):企業の財務・戦略的SWOT分析
    Summary Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug ca …
  • Sunningdale Tech Ltd (BHQ):企業の財務・戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company that manufactures and markets tooling and plastic injection moulding components. The company's plastic solutions include product and mould designs, injection moulding, mould fabrication, complementary finishings, and precision assembly …
  • TWi Pharmaceuticals Inc (4180):製薬・医療:M&Aディール及び事業提携情報
    Summary TWi Pharmaceuticals Inc (TWi), formerly Anchen Pharmaceuticals (Taiwan) Inc is a technology based pharmaceutical company that manufactures high barrier generics drugs. The company provides products such as donepezil hydrochloride tablets, hydroquinone cream, hydroquinone time release cream, …
  • SenesTech Inc (SNES):企業の財務・戦略的SWOT分析
    SenesTech Inc (SNES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The KEYW Holding Corporation:企業のM&A・事業提携・投資動向
    The KEYW Holding Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The KEYW Holding Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Knights of Columbus:企業の戦略的SWOT分析
    Knights of Columbus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Rush Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報
    Summary ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. Its pipeline drug candidates include AM0010, AM0015, AM0012, AM0003 and AM0001. ARMO Biosciences’s lead immunotherapy AM0010 is along-acting form of recombinant human Interleukin 10 (I …
  • Beverages & More Inc:企業の戦略的SWOT分析
    Beverages & More Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Press Ganey Associates Inc:企業の戦略的SWOT分析
    Press Ganey Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Bioceptive Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bioceptive Inc (Bioceptive) is a medical device company that provides medical devices for a variety of gynaecological procedures. The company offers products such as intrauterine devices, intuitive IUD insertion systems and IUD inserters, among others. Its intrauterine devices offer less tra …
  • Crane Co:企業の戦略・SWOT・財務分析
    Crane Co - Strategy, SWOT and Corporate Finance Report Summary Crane Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Agenus Inc (AGEN):企業の財務・戦略的SWOT分析
    Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Selecta Biosciences Inc (SELB):製薬・医療:M&Aディール及び事業提携情報
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (S …
  • Finley Resources Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Finley Resources Inc (Finley) is an oil and gas company that owns, manages, operates and develops oil and gas properties. The company operates its oil and gas properties in the areas of Permian Basin, South Texas, East Texas, Mississippi, Barnett Shale, San Juan Basin, Alabama, Oklahoma and …
  • Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibi …
  • DRDGOLD Ltd:企業の戦略・SWOT・財務情報
    DRDGOLD Ltd - Strategy, SWOT and Corporate Finance Report Summary DRDGOLD Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Kineta Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kineta Inc (Kineta) is a biotech company that develops novel immuno-therapies. The company offers small-molecule compounds that target RIG-I-like receptor pathways and intracellular IRF3-inducing pathways for applications in cancer. Its KCP-400 is a novel non-opioid therapy for the treatment …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆